You just read:

New XARELTO® (rivaroxaban) Data at ESC Congress 2017 Includes Late-Breaking Results from Landmark Phase 3 COMPASS Study

News provided by

Janssen Research & Development, LLC

Aug 21, 2017, 08:00 ET